🇺🇸 FDA

Intelligence · Clinical Pipeline

Oncology R&D Pipeline

Anticancer agents, immuno-oncology biologics, and oncology pipeline programs from ClinicalTrials.gov — Phase 1 through approval.

Programs
5,568

Quick answer

Oncology: NovaPharmaNews indexes 5,568 oncology clinical pipeline programs from ClinicalTrials.gov with phase, modality, NCT identifiers, and sponsor company links. Anticancer agents, immuno-oncology biologics, and oncology pipeline programs from ClinicalTrials.gov — Phase 1 through approval.

Top sponsors

Page 94 of 116

  1. Daunorubicin

    Protara Therapeutics

    Acute Lymphocytic Leukemia

    phase 1 small molecule completed

    1 trial

  2. Debio 0123 in combination with carboplatin and etoposide in adult participants with small cell lung cancer that recurred or progressed after platinum-based therapy.

    Alphapharm Pty Ltd

    Small cell lung cancer

    phase 1 other active

    1 trial

  3. Debio 0123, Debio 0123, Debio 0123, Debio 2513, Debio 0123, Debio 2513, Debio 0123, Debio 0123

    Alphapharm Pty Ltd

    Advanced solid tumors with CCNE1 amplification or deleterious mutations in FBXW7 or other proprietary gene

    phase 1 small molecule active

    1 trial

  4. Decitabine

    Foghorn Therapeutics

    Acute Myeloid Leukemia

    phase 1 small molecule active

    1 trial

  5. Demcizumab

    Mereo BioPharma Group plc

    Primary Peritoneal Carcinoma

    phase 1 small molecule terminated

    1 trial

  6. Demcizumab

    Mereo BioPharma Group plc

    Locally Advanced or Metastatic Solid Tumors

    phase 1 small molecule completed

    1 trial

  7. Demcizumab

    Mereo BioPharma Group plc

    Non Small Cell Lung Cancer

    phase 1 small molecule completed

    1 trial

  8. Dendritic Cell (DC1) Vaccine

    VACCINEX, INC.

    HER2-positive Breast Cancer

    phase 1 mab active

    1 trial

  9. Dendritic Cell Vaccination

    Quantum Biopharma

    Metastatic Breast Cancer

    phase 1 mab active

    1 trial

  10. Detection of tumor tiSsue in pEritoneal metastases of coLorectal origin using a VEGF-targeted optical fluoresCent imaging tracer during diagnosTic laparoscopy

    Disc Medicine

    peritoneal metastases of colorectal origin

    phase 1 other active

    1 trial

  11. Docetaxel

    United Therapeutics Europe Ltd

    Prostate Cancer

    phase 1 small molecule completed

    1 trial

  12. Docetaxel

    Mereo BioPharma Group plc

    Solid Tumors

    phase 1 small molecule completed

    1 trial

  13. Dociparstat sodium

    BRIGHT MINDS BIOSCIENCES INC.

    Acute Myeloid Leukemia

    phase 1 small molecule completed

    1 trial

  14. Domvanalimab

    Arcus Biosciences

    Solid Tumor, Unspecified, Adult

    phase 1 small molecule completed

    1 trial

  15. Dose dense re-challenge of high dose methotrexate (hd-mtx) with glucarpidase (cpg2) for relapsed primary cns lymphoma (pcnsl): A phase 1 trial (METHOGLU)

    Pari Pharma GmbH

    Oncology: RELAPSED PRIMARY CNS LYMPHOMA

    phase 1 other active

    1 trial

  16. Dose escalation trial of BNT152+153 in patients with cancer

    BioNTech SE

    Various solid tumors that are metastatic or unresectable

    phase 1 other active

    1 trial

  17. Doxorubicin

    United Therapeutics Europe Ltd

    Pancreatic Ductal Adenocarcinoma

    phase 1 small molecule terminated

    1 trial

  18. Drug Product De-TIL-0255

    Nurix Therapeutics

    Platinum-resistant Ovarian Cancer

    phase 1 mab terminated

    1 trial

  19. Drug-AZD8931

    AstraZeneca

    Breast Neoplasm

    phase 1 small molecule terminated

    1 trial

  20. Drug: BG-T187

    BEONE MEDICINES AUS PTY LTD

    Advanced Solid Tumor

    phase 1 small molecule active

    1 trial

  21. Dual Specificity CD19 and CD22 CAR-T Cell Immunotherapy

    Nanjing Legend Biotech Co.

    Lymphoma, B-Cell

    phase 1 small molecule terminated

    1 trial

  22. Dual Specificity CD19 and CD22 CAR-T Cell Immunotherapy

    Nanjing Legend Biotech Co.

    Refractory B Acute Lymphoblastic Leukemia

    phase 1 small molecule terminated

    1 trial

  23. Dual-Wavelength Quantitative Fluorescence Endoscopy for Optical PD-1 and PD-L1 Imaging in Locally Advanced Esophageal Cancer: A Phase I Multicenter Feasibility and Safety Study

    Disc Medicine

    Esophageal cancer

    phase 1 other active

    1 trial

  24. E7080

    Eisai Co.,

    Cancer: Solid Tumors

    phase 1 small molecule completed

    1 trial

  25. E7766

    Eisai Co.,

    Lymphoma

    phase 1 small molecule terminated

    1 trial

  26. EBV immunological agent

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Malignant Tumor

    phase 1 mab active

    1 trial

  27. ELVN-001

    Enliven Therapeutics

    CML (Chronic Myelogenous Leukemia)

    phase 1 small molecule active

    1 trial

  28. ELVN-001

    Enliven Therapeutics

    Chronic Myeloid Leukemia

    phase 1 small molecule active

    1 trial

  29. ELVN-002

    Enliven Therapeutics

    HER2 Mutant Non-small Cell Lung Cancer

    phase 1 small molecule active

    1 trial

  30. ELVN-002

    Enliven Therapeutics

    HER2-positive Breast Cancer

    phase 1 small molecule active

    1 trial

  31. EMBER: A Study of LY3484356 in Patients with Breast or Other Non-Breast Cancers

    Eli Lilly Co.

    Breast Cancer, Endometrial cancer

    phase 1 other active

    1 trial

  32. ENMD-2076

    CASI Pharmaceuticals

    Advanced Cancer

    phase 1 small molecule completed

    1 trial

  33. ES414

    Aptevo Therapeutics

    Prostate Cancer

    phase 1 mab completed

    1 trial

  34. ET1402L1-ARTEMIS™ T cells -IV

    AEON Biopharma

    Hepatocellular Carcinoma

    phase 1 mab completed

    1 trial

  35. ETC-159

    BRIGHT MINDS BIOSCIENCES INC.

    With MSS/pMMR Advanced, Platinum-resistant Ovarian Cancer

    phase 1 small molecule active

    1 trial

  36. ETC-1907206

    BRIGHT MINDS BIOSCIENCES INC.

    Ph+ Acute Lymphoblastic Leukemia (Ph+ALL)

    phase 1 small molecule terminated

    1 trial

  37. ETC-1922159

    BRIGHT MINDS BIOSCIENCES INC.

    Solid Tumors

    phase 1 small molecule active

    1 trial

  38. EVM16

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Advanced or Recurrent Solid Tumors

    phase 1 mab active

    1 trial

  39. EVOLVE104

    United Therapeutics Europe Ltd

    Bladder Cancer

    phase 1 small molecule active

    1 trial

  40. EVT801

    KAZIA THERAPEUTICS LTD

    Solid Tumor, Adult

    phase 1 small molecule completed

    1 trial

  41. EXS74539

    RECURSION PHARMACEUTICALS, INC.

    Solid Tumor

    phase 1 small molecule active

    1 trial

  42. Efficacy of LCAR-T2C CAR-T cells

    Nanjing Legend Biotech Co.

    CD4+ T Lymphocyte Tumor (T Cell Lymphoma and T Cell Leukemia)

    phase 1 small molecule terminated

    1 trial

  43. Efficacy of LCAR-T2C CAR-T cells

    Nanjing Legend Biotech Co.

    T Cell Lymphoma

    phase 1 small molecule terminated

    1 trial

  44. Elimusertib (BAY1895344)

    Bayer HealthCare AG

    Advanced Solid Tumor

    phase 1 small molecule completed

    1 trial

  45. Engineered mitochondrial vaccine

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Advanced Solid Tumor Malignancies

    phase 1 mab active

    1 trial

  46. Entinostat

    Syndax Pharmaceuticals

    Pancreas Cancer

    phase 1 small molecule terminated

    1 trial

  47. Entinostat

    Syndax Pharmaceuticals

    Neoplasms

    phase 1 small molecule completed

    2 trials

  48. Entinostat

    Syndax Pharmaceuticals

    Metastatic Breast Cancer

    phase 1 small molecule completed

    1 trial

Frequently asked questions

How many oncology pipeline programs are tracked?

5,568 programs match this therapeutic area based on indication text, program name, and registry metadata.

Where does pipeline data come from?

ClinicalTrials.gov records linked to NovaPharmaNews company profiles. Verify on ClinicalTrials.gov before investment decisions.

Data attribution: Data sources · All pipeline programs

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.